Women with submucosal uterine leiomyomas who undergo hysteroscopic removal have comparable birth outcomes to women with submucosal uterine leiomyomas who do not have hysteroscopic removal, according to a retrospective case-control study in the American Journal of Obstetrics & Gynecology MFM.
“Previous studies have demonstrated increased rates of poor obstetrical outcomes including preterm delivery, placental abruption, and intrauterine growth restriction in women with uterine leiomyomas,” wrote the authors. “Currently, preconception myomectomy has not been reported to improve pregnancy rates or pregnancy outcomes in women with subserosal leiomyomas, and the data remain inconclusive for intramural fibroids.”
Although pregnancy rates have been found to improve after the removal of submucosal fibroids, the effect of preconception myomectomy for submucosal fibroids on birth outcomes has yet to be assessed, according to the investigators.
The current study sought to determine whether hysteroscopic excision of submucosal leiomyomas impacts the rate of preterm delivery and other obstetrical outcomes.
The final chart review comprised 62 women from Christiana Care Health System in Newark, Delaware, who were diagnosed with submucosal fibroids and underwent hysteroscopic myomectomy between January 2001 and January 2014. There were also 215 controls of women with submucosal fibroids without hysteroscopic myomectomy (case-to-control ratio, 1:3).
All women delivered a nonanomalous fetus beyond 20 weeks' gestation.
Cases and controls were similar in age, race, body mass index (BMI) and mode of delivery.
Overall, 66% of cases were primiparous vs. 37% of controls (P = 0.00), whereas 22.6% of cases used assisted reproductive technology to conceive vs. 7.0% of controls (P < 0.001).
However, the study revealed no differences in the rate of preterm delivery at <37 weeks' gestation (12.9% cases vs. 13.5% controls) (P = 0.89); preterm delivery at <34 weeks' gestation (4.84% vs. 6.97%) (P= 0.77); or other obstetrical outcomes.
The chart review indicated that the causes of preterm delivery in the control population were hypertensive disorders of pregnancy (31.2%); preterm premature rupture of membranes (PPROM) (18.75%); intrauterine fetal demise (IUFD) (12.5%); nonreassuring fetal heart tracing (NRFHT) (9.3%); vaginal bleeding in the setting of placenta previa (6.25%); spontaneous preterm labor (12.5%); and unknown causes (9.3%).
For cases, the causes included PPROM (14.3%); NRFHT (14.3%); hypertensive disorders of pregnancy (14.3%); spontaneous preterm labor (14.3%); and unknown causes (42.9%).
There were no statistically significant differences in the rates of preterm birth before 34 weeks’ gestation (7.01% cases vs. 4.84% controls; P = 0.77); PPROM (0% vs. 4.7%; P = 012); placental abruption (0% vs. 1.87%; P = 0.58); fetal malpresentation (9.7% vs. 7.9%; P = 0.66); intrauterine growth restriction (IUGR) (9.7% vs. 17.4%; P = 0.14); IUFD (0% vs 2.3%; P = 0.59); retained placenta (0% vs. 0.47%; P = 0.67); postpartum hemorrhage (3.23% vs. 2.80%; P = 1.00); maternal transfusion (0% vs. 1.4%; P = 1.00); and the rate of cesarean delivery (54.8% vs. 57.5%; P = 0.71).
“Hysteroscopic myomectomy is considered a low-risk procedure, but the impact on future pregnancies is not fully understood,” wrote the authors. “Based on our findings, it seems that a composite of obstetrical outcomes is not significantly affected by hysteroscopic myomectomy, making it hard to know whether myomectomy should be offered to women with asymptomatic fibroids who are considering pregnancy.”
__
Source
doi:10.1016/j.ajogmf.2020.100192
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More